ScreenerHero

MNOV MediciNova, Inc.

NAS · US · Healthcare · Biotechnology · medicinova.com
1.610USD-2.42%Mkt Cap: 79.25M $P/E: —

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilas…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
HeadlineSourceTime
Older
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus. The exploratory study highlighted improvements in cardiovascular lipid markers, alongside positive trends in liver fat reduction and body weight loss. Phase 2 Trial Design And Efficacy Findings The MN-001-NATG-202

Benzinga
MediciNova Shares Fall After Phase 2 Tipelukast Trial Misses Primary Endpoints

MediciNova Inc (NASDAQ:MNOV) shares fell 14. 7% in premarket trading on Monday after the company reported topline results from a Phase 2 clinical trial evaluating tipelukast, or MN-001, in patients with nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus.

InvestorsHub
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data

Investing.com -- MediciNova Inc (NASDAQ:MNOV) shares fell 14.7% in premarket trading Monday following mixed results from a Phase 2 clinical trial evaluating tipelukast (MN-001) for the treatment of nonalcoholic fatty liver disease and hypertriglyceridemia associated with type 2 diabetes mellitus.

Investing.com
MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.

Stocktwits
MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

MediciNova (MNOV) delivered earnings and revenue surprises of +16.67% and +205.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks
Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of +12.50% and +283.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks